DNA damage & the DNA damage response (DDR)
The DDR is required for cell survival. Several repair pathways cooperate and sometimes compete in response to different types of DNA damage, leading to the effective maintenance of genomic material in cells.
The concept of synthetic lethality was first derived from genetic studies in model organisms, where mutation of a particular gene becomes lethal only through mutation or loss of another gene.
Ubiquitin processes in DDR
A wealth of scientific evidence shows that the post translational modification process of ubiquitylation and its reversal by deubiquitylation play key roles in regulating the DDR and associated processes.
Jul 01, 2015
CAMBRIDGE, UK – 1ST JULY 2015 – MISSION Therapeutics, a drug discovery and development company today announced Dr Colin Goddard, former Chief Executive Officer of OSI Pharmaceuticals (“OSI”), has been appointed to the Company’s Board of Directors.
Professor Steve Jackson, MISSION Therapeutics CSO and Professor of Biology, Head of Cancer Research UK laboratories at the Gurdon Institute, University of Cambridge, will be giving the 22nd Raymond and Beverly Sackler distinguished lecture on the 11th of June in Leeds and on the 25th of June in Cambridge. The title of the lecture is 'Cellular responses to DNA damage:mechanistic insights and new cancer therapies'.
Philadelphia, PA, US and Cambridge UK, 20 April 2015 – MISSION Therapeutics, a company focused on the discovery and development of modulators of the deubiquitylating (DUB) enzyme family for the treatment of cancer and other diseases, today presents a poster at AACR entitled “Discovery of highly selective UCHL1 inhibitors with in vivo pre-clinical anti-tumour activity”.
Poster exemplifies amenability of wider target family to development of drug-like molecules